(Q46448545)

English

Association between acquired rifamycin resistance and the pharmacokinetics of rifabutin and isoniazid among patients with HIV and tuberculosis

scientific article published on 14 April 2005

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/15844071

Association between acquired rifamycin resistance and the pharmacokinetics of rifabutin and isoniazid among patients with HIV and tuberculosis (English)

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/15844071

0 references

1 reference

based on heuristic

inferred from title

pharmacokinetics

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

0 references

author name string

Marc Weiner

1

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/15844071

Debra Benator

2

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/15844071

William Burman

3

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/15844071

Charles A Peloquin

4

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/15844071

Awal Khan

5

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/15844071

Andrew Vernon

6

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/15844071

Brenda Jones

7

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/15844071

Claudia Silva-Trigo

8

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/15844071

Zhen Zhao

9

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/15844071

Thomas Hodge

10

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/15844071

Tuberculosis Trials Consortium

11

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/15844071

language of work or name

0 references

publication date

14 April 2005

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/15844071

Clinical Infectious Diseases

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/15844071

40

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/15844071

10

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/15844071

1481-1491

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/15844071

Tuberculosis treatment outcomes: directly observed therapy compared with self-administered therapy.

1 reference

https://api.crossref.org/works/10.1086%2F429321

21 January 2018

Rifampin-monoresistant tuberculosis in New York City, 1993-1994.

1 reference

https://api.crossref.org/works/10.1086%2F429321

21 January 2018

Risk factors for rifampin-monoresistant tuberculosis: A case-control study.

1 reference

https://api.crossref.org/works/10.1086%2F429321

21 January 2018

Risk factors for rifampin mono-resistant tuberculosis.

1 reference

https://api.crossref.org/works/10.1086%2F429321

21 January 2018

Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: a randomised clinical trial

1 reference

https://api.crossref.org/works/10.1086%2F429321

21 January 2018

Risk factors for relapse and acquired rifamycin resistance after directly observed tuberculosis treatment: a comparison by HIV serostatus and rifamycin use.

1 reference

https://api.crossref.org/works/10.1086%2F429321

21 January 2018

American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America

1 reference

https://api.crossref.org/works/10.1086%2F429321

21 January 2018

A model based assessment of redistribution dependent elimination and bioavailability of rifabutin

1 reference

https://api.crossref.org/works/10.1086%2F429321

21 January 2018

Low isoniazid concentrations and outcome of tuberculosis treatment with once-weekly isoniazid and rifapentine

1 reference

https://api.crossref.org/works/10.1086%2F429321

21 January 2018

Isoniazid pharmacokinetics-pharmacodynamics in an aerosol infection model of tuberculosis

1 reference

https://api.crossref.org/works/10.1086%2F429321

21 January 2018

Role of Isoniazid in Once-Weekly Rifapentine Treatment of Pulmonary Tuberculosis

1 reference

https://api.crossref.org/works/10.1086%2F429321

21 January 2018

Pharmacokinetics-pharmacodynamics of rifampin in an aerosol infection model of tuberculosis

1 reference

https://api.crossref.org/works/10.1086%2F429321

21 January 2018

Pharmacokinetics of rifapentine at 600, 900, and 1,200 mg during once-weekly tuberculosis therapy

1 reference

https://api.crossref.org/works/10.1086%2F429321

21 January 2018

Therapeutic drug monitoring in the treatment of tuberculosis

1 reference

https://api.crossref.org/works/10.1086%2F429321

21 January 2018

HIV-1 and recurrence, relapse, and reinfection of tuberculosis after cure: a cohort study in South African mineworkers

1 reference

https://api.crossref.org/works/10.1086%2F429321

21 January 2018

Identifiers

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/15844071

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/15844071

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46448545&oldid=2112030404"